Global Human Growth Hormone Drugs Market to Reach US$4.7 Billion by 2018, According to New Report by Global Industry Analysts, Inc.

GIA announces the release of a comprehensive global report on the Human Growth Hormone Drugs markets. The global market for Human Growth Hormone (hGH) Drugs is forecast to reach US$4.7 billion by the year 2018. Major factors driving future growth in the market include high prevalence of growth hormone deficiency, improved delivery devices, development of novel drug delivery methods, and increasing indications of growth hormones.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Human Growth Hormone Drugs: A Global Strategic Business Report

San Jose, California (PRWEB) August 16, 2012

Follow us on LinkedIn – Use of human growth hormone (hGH) or somatotropin gained momentum and became a mainstream therapeutic product in recent years. hGH drugs have been available in the market for several years and some of the first wave of products have gone off-patent while some others are nearing their patent expiry. This led to the infusion of biosimilars or follow-on protein products into the market, with Sandoz’ Omnitrope and LG LifeSciences’ Valtropin pioneering this market. Despite being offered at around 20-25% discount over the price of their originators, these drugs have failed to make any large impact on the market. Meanwhile, manufacturers of originator drugs began emphasizing on offering novel delivery methods and devices in order to alleviate the impact of biosimilars. Not only has this move assisted them in holding on to their customer base to a large extent but also enhanced uptake of hGH drugs due to the relative ease and convenience offered. New routes of drug administration, currently being investigated, such as nasal and oral formulations are further expected to surge demand for these products in volume terms. Additionally, given the higher frequency of hGH injections that are required to be administered, improvements in this front are also expected to expand uptake from more and more patients.

hGH products cater to two different markets – vanity market and treatment of growth hormone deficiency. Products targeting the vanity market are non-prescription drugs, which are primarily targeted for use in adults to enhance physical performance or in checking the aging process. Several companies are engaged in offering these products, mostly at low prices. However, these over-the-counter products are marred with limited efficacy and activity, given the lower bioavailability of these oral medications. On the other side, prescription hGH products are targeted for use in both adults and children, mainly for the treatment of growth hormone deficiency. These injectable prescription drugs possess higher bioavailability when compared to the oral treatments, as a result of which the price of prescription hGH products is often high. These include products such as Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope and Saizen among others. Virtually all prescription growth hormone products available in the market are similar with respect to their clinical effects. Most vagaries seen in approved indications reflect those sought by respective manufacturers for approvals. In terms of delivery, most existing products are required to be administered almost daily, while certain products require thrice-weekly administration.

Biosimilar hGH products, or generic somatropin products, emerged over the previous decade with some of the first line of biopharmaceutical hGH products going off-patent and some more nearing their expiry. Biosimilar hGH products emerged in the US, Europe, Japan, Korea and Australian markets; however, regulatory setup with respect to approvals of biosimilar products is relatively more established in the EU region. The year 2006 witnessed the influx of generic competition into the hGH market, with the first biosimilar being approved in Europe during the year, followed by a similar approval in the US in the very next year. With the emergence of biosimilars in the market and looming patent expiries of some of the leading market drugs, development of long-acting hGH products began gathering steam from producers of original drugs. Major companies such as Prolor Biotech, Merck and Novo Nordisk are developing long-acting versions of their products, with most of the products completing phase II clinical trials.

Biobetters or the follow-on branded biologic drugs have played a critical role in restricting the penetration of biosimilars, which is pertinent even in the hGH market. Branded biologic manufacturers have been swift in moving towards safeguarding their market shares by launching upgrades to their off-patent biologics. The most common feature of these biobetters has been the sustained-release formulation of existing drugs, which engender enhanced convenience and prolonged effect. More specifically in the hGH market, differentiation of quality has been a major hindrance for wider adoption of biosimilars. Consequently, drug selection involved consideration of other aspects such as brand loyalty, insurance coverage and the timing of the launch. Pertinently, biosimilars have been relegated to occupy a trivial share in the market, while multinational pharmaceutical companies continue to dominate the market. Also, due to these factors, around 25% price discount that come with biosimilar products have largely failed to incite a change in patient’s or physician’s selection of products.

The US represents the largest regional market worldwide, as stated by the new market research report on Human Growth Hormone Drugs. Demand for hGH products began to surge in the US after the US FDA began granting approvals for new hGH products. The emergence of approved products, especially for specific indications, led to substantial increase in the number of patients diagnosed with these conditions. However, Europe is projected to emerge as the fastest growing regional market worldwide, witnessing a projected compounded annual growth rate of 5.5% over the analysis period.

Major players profiled in the report include Eli Lilly and Company, Ferring Pharmaceuticals A/S, Genentech, Inc., GeneScience Pharmaceuticals Co., Ltd., Merck Serono SA, Sandoz International GmbH, Novo Nordisk A/S, Pfizer, Inc., and Teva Pharmaceutical Industries Limited.

The research report titled “Human Growth Hormone Drugs: A Global Strategic Business Report” announced by Global Industry Analysts, Inc., provides comprehensive market overview, market trends & issues, product trends, market share data, recent industry activity and profiles of leading companies in the market. Analysis and overview is provided for the years 2009 through 2018 in US$ million for the global market and major geographic markets such as the US, Japan, Europe, and Rest of World.

For more details about this comprehensive market research report, please visit –
http://www.strategyr.com/Human_Growth_Hormone_Drugs_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

###


Contact

Attachments